81 related articles for article (PubMed ID: 8230809)
1. Immunological comparison of intracellular toxin A and extracellular toxin A from Clostridium difficile.
Meng XQ; Yamakawa K; Ogura H; Nakamura S
Jpn J Med Sci Biol; 1993 Feb; 46(1):51-6. PubMed ID: 8230809
[TBL] [Abstract][Full Text] [Related]
2. Haemagglutination activity of toxigenic and non-toxigenic strains of Clostridium difficile.
Meng XQ; Yamakawa K; Ogura H; Nakamura S
FEMS Microbiol Lett; 1994 May; 118(1-2):141-4. PubMed ID: 8013869
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile.
Martinez RD; Wilkins TD
J Med Microbiol; 1992 Jan; 36(1):30-6. PubMed ID: 1370542
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of immunological properties and cytotoxic effects of Clostridium difficile toxin B and Clostridium sordellii toxin L.
Baldacini O; Girardot R; Green GA; Rihn B; Monteil H
Toxicon; 1992 Feb; 30(2):129-40. PubMed ID: 1557784
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
[TBL] [Abstract][Full Text] [Related]
6. Antigenicity of amino-acid sequences from Clostridium difficile toxin B.
Torres JF; Monath TP
J Med Microbiol; 1996 Jun; 44(6):464-74. PubMed ID: 8636964
[TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin).
Martinez RD; Wilkins TD
Infect Immun; 1988 May; 56(5):1215-21. PubMed ID: 3128481
[TBL] [Abstract][Full Text] [Related]
8. Production of monoclonal antibody to Clostridium difficile toxin A which neutralizes enterotoxicity but not haemagglutination activity.
Kamiya S; Yamakawa K; Meng XQ; Ogura H; Nakamura S
FEMS Microbiol Lett; 1991 Jul; 65(3):311-5. PubMed ID: 1916231
[TBL] [Abstract][Full Text] [Related]
9. Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.
Quemeneur L; Petiot N; Arnaud-Barbe N; Hessler C; Pietrobon PJ; Londoño-Hayes P
Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632249
[No Abstract] [Full Text] [Related]
10. [Preparation and characterization of monoclonal antibody against Clostridium difficile toxin A].
Fu SW; Zhou DY; Lai ZS; Xue J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):376-8. PubMed ID: 15193243
[TBL] [Abstract][Full Text] [Related]
11. Purification and characterisation of intracellular toxin A of Clostridium difficile.
Meng XQ; Kamiya S; Yamakawa K; Ogura H; Nakamura S
J Med Microbiol; 1993 Jan; 38(1):69-73. PubMed ID: 8418298
[TBL] [Abstract][Full Text] [Related]
12. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.
Kelly CP; Pothoulakis C; Vavva F; Castagliuolo I; Bostwick EF; O'Keane JC; Keates S; LaMont JT
Antimicrob Agents Chemother; 1996 Feb; 40(2):373-9. PubMed ID: 8834883
[TBL] [Abstract][Full Text] [Related]
13. Detection of Clostridium difficile toxin A by reversed passive latex agglutination.
Toma C; Nakamura S; Kamiya S; Nakasone N; Iwanaga M
Microbiol Immunol; 1999; 43(8):737-42. PubMed ID: 10524790
[TBL] [Abstract][Full Text] [Related]
14. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.
Johnson S; Gerding DN; Janoff EN
J Infect Dis; 1992 Dec; 166(6):1287-94. PubMed ID: 1431247
[TBL] [Abstract][Full Text] [Related]
15. Immunochemical and structural similarities in toxin A and toxin B of Clostridium difficile shown by binding to monoclonal antibodies.
Rothman SW; Gentry MK; Brown JE; Foret DA; Stone MJ; Strickler MP
Toxicon; 1988; 26(6):583-97. PubMed ID: 2459808
[TBL] [Abstract][Full Text] [Related]
16. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease.
Johnson S; Sypura WD; Gerding DN; Ewing SL; Janoff EN
Infect Immun; 1995 Aug; 63(8):3166-73. PubMed ID: 7622244
[TBL] [Abstract][Full Text] [Related]
17. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers.
Stubbe H; Berdoz J; Kraehenbuhl JP; Corthésy B
J Immunol; 2000 Feb; 164(4):1952-60. PubMed ID: 10657645
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea.
Bacon AE; Fekety R
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):205-9. PubMed ID: 7924215
[TBL] [Abstract][Full Text] [Related]
19. Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide.
Wren BW; Russell RR; Tabaqchali S
Infect Immun; 1991 Sep; 59(9):3151-5. PubMed ID: 1715320
[TBL] [Abstract][Full Text] [Related]
20. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
